Boston Scientific to Invest €30m in Cork RD&I

Boston Scientific Corporation today announced a €30 million investment in its Cork facility to accelerate the development and manufacturing of minimally-invasive medical technologies that treat patients suffering from cancer and peripheral arterial diseases around the world.

This research, development, and innovation (RD&I) investment, which is supported by the Irish Government through IDA Ireland, will further diversify the range of technologies developed and manufactured at the Boston Scientific Cork site and is expected to generate more than 70 new quality, engineering and production jobs over the next three years.

The Boston Scientific site currently employs more than 1,200 people and makes medical devices for interventional oncology, coronary artery disease, digestive disorders and severe asthma.

“I am really pleased that the Boston Scientific Corporation has announced this significant €30 million investment in its Cork facility,” said Tánaiste and Minister for Enterprise, Trade & Employment Leo Varadkar TD. “This investment will allow the company to grow and develop its world-leading technologies and ensure that it continues helping to improve and save lives.

Ireland is globally recognised as a centre of excellence for the Life Sciences and this investment is a real vote of confidence in us and our capacity. I wish the team the very best with their plans.”

“Boston Scientific has had a strong presence in the Cork business community for nearly 25 years,” said Martin Shanahan, CEO, IDA Ireland. “As the company grows and expands into more therapeutic areas through internal RD&I and acquisitions its continued investment in ongoing operations and highly skilled local talent is encouraging. This expansion is further evidence of the southwest region’s thriving MedTech cluster.”

More information can be found here.